This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases examined whether agalsidase beta enzyme replacement therapy improves long-term kidney function and reduces clinical events by comparing real-world data from treated Fabry patients to matched untreated individuals with similar characteristics, age, and kidney function.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Reduction in kidney function decline and risk of severe clinical events in agalsidase beta–treated Fabry disease patients: a matched analysis from the Fabry Registry’ and was published in the Clinical Kidney Journal.

Visit Oxford Academic using the link to read the original article.